U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H14F3N5O
Molecular Weight 349.3105
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORICONAZOLE

SMILES

C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3

InChI

InChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H14F3N5O
Molecular Weight 349.3105
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00582

Voriconazole (vor-i-KON-a-zole, brand name Vfend, Pfizer) is a triazole antifungal medication. VFEND® (voriconazole) is available as film-coated tablets for oral administration, and as a lyophilized powder for solution for intravenous infusion. Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems. The most common side effects associated with voriconazole include transient visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, and respiratory disorder. Unlike most adverse effects, which are similar to other azole antifungal agents, visual disturbances (such as blurred vision or increased sensitivity to light) are unique to voriconazole. Though rare, there have been cases of serious hepatic reactions during treatment with voriconazole (a class effect of azole antifungal agents). Liver function tests should be evaluated at the start of and during the course of therapy. Voriconazole is phototoxic. It has been associated with an increased risk of squamous-cell carcinoma of the skin

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

2003
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

2003
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

2003
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.13 μg/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.31 μg/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.03 μg/mL
3 mg/kg 2 times / day steady-state, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.77 μg/mL
4 mg/kg 2 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.74 μg/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.3 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.1 μg/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13.9 μg × h/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.4 μg × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.7 μg × h/mL
3 mg/kg 2 times / day steady-state, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33.9 μg × h/mL
4 mg/kg 2 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
34 μg × h/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9.31 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
27.9 μg × h/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.5 h
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
42%
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
42%
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Photophobia, Fatigue...
AEs leading to
discontinuation/dose reduction:
Photophobia (1 patient)
Fatigue (1 patient)
Concentration impaired (1 patient)
Insomnia (1 patient)
Sources:
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Disc. AE: Function liver abnormal, Hallucination, visual...
AEs leading to
discontinuation/dose reduction:
Function liver abnormal (73 patients)
Hallucination, visual (16 patients)
Skin rash (6 patients)
Kidney dysfunction (3 patients)
Electrocardiogram QTc interval prolonged (2 patients)
Gastrointestinal symptom NOS (1 patient)
Sources:
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
n = 31
Health Status: unhealthy
Condition: Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others
Age Group: 53.4–67.5 years
Sex: M+F
Population Size: 31
Sources:
Disc. AE: CRP increased, Bilirubin increased...
AEs leading to
discontinuation/dose reduction:
CRP increased (31 patient)
Bilirubin increased (31 patient)
Sources:
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and invasive aspergillosis
Age Group: 9 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Photophobia...
AEs leading to
discontinuation/dose reduction:
Photophobia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Concentration impaired 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Fatigue 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Insomnia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Photophobia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Gastrointestinal symptom NOS 1 patient
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Hallucination, visual 16 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Electrocardiogram QTc interval prolonged 2 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Kidney dysfunction 3 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Skin rash 6 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Function liver abnormal 73 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Bilirubin increased 31 patient
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
n = 31
Health Status: unhealthy
Condition: Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others
Age Group: 53.4–67.5 years
Sex: M+F
Population Size: 31
Sources:
CRP increased 31 patient
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
n = 31
Health Status: unhealthy
Condition: Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others
Age Group: 53.4–67.5 years
Sex: M+F
Population Size: 31
Sources:
Photophobia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and invasive aspergillosis
Age Group: 9 years
Sex: M
Population Size: 1
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96% and fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 2, 10,13, 21-23, 26-27
no
no
no
yes [Km 21 uM]
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 11.0
yes [Km 240 uM]
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 11.0
PubMed

PubMed

TitleDatePubMed
[New antifungal drugs. Present and future].
1999 Sep
[Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
2001
Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia.
2001
Coccidioidomycosis: efficacy of new agents and future prospects.
2001 Dec
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
2001 Mar
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
2001 Nov 1
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.
2002
Pharmacological aspects of the new triazole voriconazole.
2002
Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.
2002
Six novel antimycotics.
2002
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.
2002 Apr
Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
2002 Dec
Case Reports. Chronic and acute Aspergillus meningitis.
2002 Dec
Voriconazole versus amphotericin B for invasive aspergillosis.
2002 Dec 19
Voriconazole versus amphotericin B for invasive aspergillosis.
2002 Dec 19
Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
2002 Jan 24
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
2002 Jul
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.
2002 Jul
Voriconazole.
2002 Jul 22
E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
2002 Jun
New drugs, old drugs - dear drugs, cheap drugs.
2002 Jun 15
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
2002 Mar
Broth medium for microdilution susceptibility tests of fluconazole and voriconazole.
2002 May
Hypercalcemia induced by 13-cis-retinoic acid in a patient with neuroblastoma.
2002 May
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
2002 May 30
Management of mycoses in patients with hematologic disease and cancer -- review of the literature.
2002 May 31
Management of mycoses in surgical patients -- review of the literature.
2002 May 31
Gateways to clinical trials.
2002 Nov
The safety of voriconazole.
2002 Nov 15
[Antifungal treatments].
2002 Nov 30
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature.
2002 Sep
Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil.
2002 Sep
Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.
2003 Feb
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
2003 Feb
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
2003 Jan
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
2003 Jan
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: I.V. for Injection requires reconstitution to 10 mg/mL and subsequent dilution to 5 mg/mL or less prior to administration as an infusion, at a maximum rate of 3 mg/kg per hour over 1-2 hours
Tablets should be taken at least one hour before, or one hour following, a meal.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The in vitro data obtained suggest that voriconazole may be effective in the treatment of opportunistic fungal infections.These investigators also noted that voriconazole was significantly more effective than itraconazole in reducing Aspergillus content in the lungs of immunocompromised animals with pulmonary aspergillosis.
each microdilution well containing 100 ul of the drug concentrations was inoculated with 100 ul of the diluted inoculum suspension (final volume in each well was 200 ul). Drug concentrations were 0.03 to 16 mg/ml for voriconazole. Stock inoculum suspensions of the molds were prepared from 7-day (Aspergillus spp., Bipolaris spp., P. boydii, R. arrhizus, and S. schenckii) or 7- to 10-day (B. dermatitidis and H. capsulatum) cultures grown on PDA at 35°C (cultures for Fusarium spp. were grown at 35°C for 48 to 72 h and then at 25 to 28°C until day 7
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:52:13 GMT 2023
Edited
by admin
on Fri Dec 15 15:52:13 GMT 2023
Record UNII
JFU09I87TR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VORICONAZOLE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
4-PYRIMIDINEETHANOL, A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-, (.ALPHA.R,.BETA.S)-
Common Name English
VORICONAZOLE [ORANGE BOOK]
Common Name English
UK-109,496
Code English
voriconazole [INN]
Common Name English
UK-109496
Code English
(.ALPHA.R,.BETA.S)-A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-4-PYRIMIDINEETHANOL
Common Name English
VORICONAZOLE [JAN]
Common Name English
VORICONAZOLE [USP-RS]
Common Name English
VFEND
Brand Name English
NSC-759888
Code English
VORICONAZOLE [MART.]
Common Name English
VORICONAZOLE [EMA EPAR]
Common Name English
VORICONAZOLE [MI]
Common Name English
Voriconazole [WHO-DD]
Common Name English
VORICONAZOLE [USAN]
Common Name English
VORICONAZOLE [EP MONOGRAPH]
Common Name English
VORICONAZOLE [USP MONOGRAPH]
Common Name English
VORICONAZOLE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C514
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
NDF-RT N0000008217
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
WHO-ATC J02AC03
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
WHO-VATC QJ02AC03
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
NDF-RT N0000175487
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
LIVERTOX NBK547891
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
Code System Code Type Description
RXCUI
121243
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY RxNorm
MESH
C102790
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
DRUG BANK
DB00582
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
USAN
LL-48
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
SMS_ID
100000088018
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
EVMPD
SUB00087MIG
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
CHEBI
10023
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
WIKIPEDIA
Voriconazole
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
ChEMBL
CHEMBL638
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
CAS
137234-62-9
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID5046485
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
MERCK INDEX
m11501
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C1707
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
DAILYMED
JFU09I87TR
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
INN
7269
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
RS_ITEM_NUM
1718008
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
NSC
759888
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
FDA UNII
JFU09I87TR
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
PUBCHEM
71616
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
DRUG CENTRAL
2846
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Dec 15 15:52:13 GMT 2023 , Edited by admin on Fri Dec 15 15:52:13 GMT 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
SALT/SOLVATE -> PARENT
BINDER->LIGAND
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/ml).
BINDING
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
METABOLIC ENZYME -> INHIBITOR
IC50
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
METABOLIC ENZYME -> INHIBITOR
IC50
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE LESS ACTIVE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC
Cmax PHARMACOKINETIC Dose

Route

Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC AT STEADY-STATE

Tmax PHARMACOKINETIC